Investigational Drug Information for PF-05221304
✉ Email this page to a colleague
What is the development status for investigational drug PF-05221304?
PF-05221304 is an investigational drug.
There have been 11 clinical trials for PF-05221304.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 22nd 2017.
The most common disease conditions in clinical trials are Liver Diseases, Fatty Liver, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Pfizer, Columbia University, and Henry N. Ginsberg.
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for PF-05221304
US Patents | 2 |
International Patents | 42 |
US Patent Applications | 22 |
WIPO Patent Applications | 11 |
Japanese Patent Applications | 4 |
Clinical Trial Progress | Phase 2 (2017-08-22) |
Vendors | 21 |
Recent Clinical Trials for PF-05221304
Title | Sponsor | Phase |
---|---|---|
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Pfizer | Phase 1 |
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Columbia University | Phase 1 |
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Henry N. Ginsberg | Phase 1 |
Clinical Trial Summary for PF-05221304
Top disease conditions for PF-05221304
Top clinical trial sponsors for PF-05221304
US Patents for PF-05221304
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
PF-05221304 | ⤷ Try a Trial | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
PF-05221304 | ⤷ Try a Trial | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-05221304
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
PF-05221304 | Canada | CA2811033 | 2030-09-30 | ⤷ Try a Trial |
PF-05221304 | Cyprus | CY1118016 | 2030-09-30 | ⤷ Try a Trial |
PF-05221304 | Denmark | DK2621493 | 2030-09-30 | ⤷ Try a Trial |
PF-05221304 | European Patent Office | EP2621493 | 2030-09-30 | ⤷ Try a Trial |
PF-05221304 | Spain | ES2602111 | 2030-09-30 | ⤷ Try a Trial |
PF-05221304 | Croatia | HRP20161178 | 2030-09-30 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |